Free Trial

ORIC Pharmaceuticals (ORIC) Stock Forecast & Price Target

ORIC Pharmaceuticals logo
$8.50 -0.33 (-3.74%)
(As of 11/15/2024 ET)

ORIC Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
8

Based on 8 Wall Street analysts who have issued ratings for ORIC Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for ORIC.

Consensus Price Target

$18.29
115.13% Upside
According to the 8 analysts' twelve-month price targets for ORIC Pharmaceuticals, the average price target is $18.29. The highest price target for ORIC is $21.00, while the lowest price target for ORIC is $14.00. The average price target represents a forecasted upside of 115.13% from the current price of $8.50.

ORIC Analyst Ratings Over Time

TypeCurrent Forecast
11/17/23 to 11/16/24
1 Month Ago
10/18/23 to 10/17/24
3 Months Ago
8/19/23 to 8/18/24
1 Year Ago
11/17/22 to 11/17/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.29$18.00$17.60$16.29
Forecasted Upside115.13% Upside96.72% Upside89.25% Upside138.10% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ORIC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ORIC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ORIC Pharmaceuticals Stock vs. The Competition

TypeORIC PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside115.13% Upside28,534.42% Upside9.87% Upside
News Sentiment Rating
Neutral News

See Recent ORIC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/12/2024Wedbush
4 of 5 stars
 Reiterated RatingOutperform$20.00+94.93%
11/4/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00+123.17%
10/31/2024Wells Fargo & Company
3 of 5 stars
D. Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$20.00+112.31%
9/23/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
9/6/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$20.00+110.97%
8/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$17.00 ➝ $15.00+81.16%
Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

5/7/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$15.00 ➝ $14.00+44.93%
3/27/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$19.00 ➝ $18.00+33.83%
8/16/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$15.00 ➝ $27.00+209.28%
3/21/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$15.00+234.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:41 PM ET.


ORIC Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for ORIC Pharmaceuticals is $18.29, with a high forecast of $21.00 and a low forecast of $14.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.

According to analysts, ORIC Pharmaceuticals's stock has a predicted upside of 115.13% based on their 12-month stock forecasts.

ORIC Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Stifel Nicolaus, Wedbush, and Wells Fargo & Company in the past 90 days.

Analysts like ORIC Pharmaceuticals more than other "medical" companies. The consensus rating for ORIC Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ORIC compares to other companies.


This page (NASDAQ:ORIC) was last updated on 11/16/2024 by MarketBeat.com Staff
From Our Partners